This site is intended only for healthcare professionals resident in the United Kingdom

Information relating to specific disease areas aligned to Pfizer’s portfolio and other resources designed for Pfizer medicines.

See all Therapy areas

For Inflectra® (infliximab) Prescribing Information for Great Britain click here.
For Inflectra® (infliximab) Prescribing Information for Northern Ireland click here
Adverse event reporting information can be found at the bottom of the page.

PROSIT-BIO

Efficacy

The primary endpoint was the evaluation of safety in terms of rate of SAEs along the first year since the introduction of the CT-P13 biosimilar in Italy.1

A secondary endpoint was efficacy evaluated both in terms of clinical remissions/response and treatment persistency.

Evaluation of the secondary endpoints demonstrated no significant difference in the estimated probability of response between the 3 treatment groups (log-rank test, p=0.64).1

Secondary endpoints: Probability of response (KM estimates) or primary failure at 8 weeks# by subgroup (n=434).1​​​​​​​​​​​​​​

No significnat difference in the estimated probability of response was found between the 3 treatment groups (log-rank test, p=0.64).1
Created from Fiorino G, et al. 2017. 

Explore more

Crohn’s disease safety

Learn about the safety profile of Inflectra in patients with Crohn’s disease

Learn more

Crohn’s disease dosing

Learn about the dosing and administration of Inflectra in patients with Crohn’s disease

Find out more

#Data at the 8-week time point were calculated after the first 8 weeks; therefore 8 weeks actually represents 16 weeks from the start of treatment. 18.6% (74/399) of the overall cohort’s responders at Week 8 lost response during follow-up, which includes from Week 8 onward.
KM=Kaplan-Meier; SAE=Serious adverse event; AE=Adverse event.
References
  1. Fiorino G, et al. Inflamm Bowel Dis 2017. 23:233–243.
PP-IFA-GBR-0502. September 2021

Quick Links

  • GONCZI L et al

  • Study 3.4

  • NOR-SWITCH safety

  • NOR-SWITCH efficacy

  • PROSIT-BIO safety

  • PROSIT-BIO efficacy

  • PROSIT-BIO study design

  • Switch studies

  • Paediatric studies

  • Induction & Maintenance

  • Inflammatory bowel disease

Learn about the mechanism of action of Infliximab.

The card body Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam.

Find out more

** This is an optional area where footnotes can live.

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-2688. December 2020

Yes

No